KH658 / Chengdu Kanghong Pharma - LARVOL DELTA

Biodistribution in ocular tissues after suprachoroidal injection of KH658 in cynomolgus monkeys (ASGCT 2025) - "The transgene and transgene product of KH658 were predominantly distributed within the retina, choroid, and sclera, which is consistent with the characteristics of suprachoroidal injection. The high concentration of anti-VEGF transgene products within the retina suggests that suprachoroidal administration of KH658 may represent a treatment option for nAMD. Disease Focus of Abstract:Ophthalmic Diseases"

Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration (GlobeNewswire) - "Chengdu Origen Biotechnology Co., Ltd. ('Chengdu Origen') and Vanotech Ltd. ('Vanotech') announced today the first patient dosed in the VAN-2401 multi-center Phase 1 clinical trial evaluating treatment with KH658 for patients with wet Age-related Macular Degeneration (wet AMD). This multi-center, open-label, dose-escalation clinical trial in the U.S. will assess the safety, tolerability and efficacy of KH658 as a single suprachoroidal space administration of gene therapy for patients with previously treated wet AMD."

Trial status • Wet Age-related Macular Degeneration

Safety profile of a suprachoroidal space injection of KH658 in rhesus monkeys (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants with Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Chengdu Origen Biotechnology Co., Ltd.

New P1 trial • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1/2 | N=44 | Recruiting | Sponsor: Chengdu Origen Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Gene therapy • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1/2 | N=44 | Not yet recruiting | Sponsor: Chengdu Origen Biotechnology Co., Ltd.

Gene therapy • New P1/2 trial • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration